CGBio has launched an innovative bone substitute material called NOVOSIS PUTTY. This advanced material incorporates recombinant human bone morphogenetic protein 2 (rhBMP-2).
The second-generation product, NOVOSIS PUTTY, showcases a ceramic-based synthetic scaffold renowned for its exceptional moldability and osteoconductive characteristics. It also integrates state-of-the-art sustained-release formulation technology (SLOREL™), an enhancement derived from its forerunner, NOVOSIS Ortho.
A pivotal component of NOVOSIS PUTTY is rhBMP-2, a protein that plays a vital role in bone regeneration by converting stem cells into bone cells to address defects.
Hydroxyapatite (HA) ceramic in NOVOSIS PUTTY acts as a dual-purpose bone graft substitute and scaffold for rhBMP-2. This enables controlled rhBMP-2 release, reducing the risk of unwanted bone growth and swelling compared to collagen sponge-based scaffolds. It also supports high-density bone formation with lower rhBMP-2 doses. The synthetic polymer hydrogel, Poloxamer 407, enhances material shaping.
The breakthrough device designation for NOVOSIS PUTTY underscores the rapid introduction of valuable products to the market, aiming to aid more patients in overcoming diseases and restoring them to healthy lives with the help of NOVOSIS PUTTY.
